Palisade BIO, Inc. (PALI) intrinsic value & 10-year financials
Palisade BIO, Inc. (PALI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 47.8% a year to $0, with an average return on invested capital of 2405.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.41
- Market cap
- $78.5M
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- 47.8%
- ROIC (10-yr avg)
- 2405.3%
- Free cash flow (FY2025)
- —
PALI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$16.8M | -$0.30 | — | — | 775.3% |
| FY2024 | $0 | -$14.4M | -$0.26 | -$12.2M | — | 885.0% |
| FY2023 | $250.0K | -$12.3M | -$0.05 | -$11.1M | -5228.0% | 3620.5% |
| FY2022 | $0 | -$14.3M | -$0.05 | -$13.4M | — | 1149.2% |
| FY2021 | — | -$26.6M | -$0.01 | -$14.8M | — | 3281.0% |
| FY2020 | $13.5K | -$16.3M | -$0.01 | -$9.0M | -78961.1% | -3278.3% |
| FY2019 | $15.4K | -$8.4M | — | — | -56071.8% | -5232.2% |
| FY2018 | $260.0K | -$4.9M | — | -$7.7M | -3176.7% | -67.6% |
| FY2017 | $260.0K | -$15.7M | — | -$13.4M | -5118.1% | 9891.1% |
| FY2016 | $16.2K | -$21.1M | — | -$15.7M | -127027.2% | 13029.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PALISADE BIO, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
PALISADE BIO, INC. has earned high returns on invested capital, averaging 17.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
PALISADE BIO, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PALISADE BIO, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-9.96 per share.